rivaroxaban granule · RIVAROXABAN 155 mg/1 · For Suspension · Oral · Lupin Pharmaceuticals, Inc.
NDC 70748-0355-01 · 1 BOTTLE in 1 CARTON / 1 FOR SUSPENSION in 1 BOTTLE · ANDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Lupin Pharmaceuticals, Inc. | RIVAROXABAN 155 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "rivaroxaban granule — NDC 70748-0355-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70748035501.
Free to cite with attribution — see how the data is put together.